Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Biogen Inc BIIB

Healthcare Biotechnology
Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology... see more

Opinion & Analysis (NDAQ:BIIB)

Could There Finally Be an Effective Treatment for Alzheimer's Disease?

Streetwise Reports November 7, 2019

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings

Streetwise Reports October 23, 2019

U.S. Biotech Makes 'The Acquisition We Were Waiting For'

Streetwise Reports March 7, 2019

Potential Alzheimer's therapies focus on early intervention

Streetwise Reports December 1, 2017

Big biotech's value is bolstered by focus on Alzheimer's disease

The Life Sciences Report November 1, 2017

Possible 'best-in-class' alzheimer's drug candidate offers 'disruptive' potential

The Life Sciences Report September 21, 2017

Biotech with Alzheimer's focus makes progress on several fronts

The Life Sciences Report July 19, 2017

Radioimmunotherapy 2.0:Actinium sets eyes on bone marrow transplant and AML with later stage programs

The Life Sciences Report August 17, 2016

BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

Gail Dutton October 1, 2015

Novel technology platforms with dramatic growth potential: Wedbush's David Nierengarten

George S. Mack August 26, 2015

The Other Bearish Biotech ETF Is Looking Groovy, Too

Benzinga.com  August 21, 2015

Using ETFs To Run Your Own Hedge Fund

Benzinga.com  August 20, 2015

A Big Day For Biotech And It's Not Going So Well

Benzinga.com  July 27, 2015

A Look Ahead: Biotech And Energy ETFs To Watch This Week

Benzinga.com  July 27, 2015

Zacks' Jason Napodano is not focused on a biotech bubble

George S. Mack July 9, 2015

3 Biotech ETFs Rally On Merger News

Benzinga.com  December 8, 2014

Buy These Top Ranked ETFs on Solid Biotech Stock Earnings - ETF News And Commentary

Benzinga.com  October 30, 2014

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary

Benzinga.com  August 27, 2014

Frank Holmes: Second quarter earnings: marching toward a strong recovery

Frank Holmes  July 29, 2014

Biotechs Struggling To Find A Bottom

Benzinga.com  April 8, 2014